• New Phase III trial data suggests giving colon cancer patients Roche's oral anticancer drug Xeloda in combination with intravenous oxaliplatin immediately after surgery boosts disease-free survival compared with combined postsurgery chemotherapy using 5-fluorouracil/leucovorin. (genengnews.com)
  • THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 3, 2006--Amgen (Nasdaq:AMGN), the world's largest biotechnology company, today announced pivotal Phase 3 results demonstrating that panitumumab significantly improved progression-free survival and disease control (response rate and stable disease) compared to best supportive care (BSC) in metastatic colorectal cancer patients who had failed standard chemotherapy. (amgen.com)
  • The use of trastuzumab, chemotherapy and surgery among women with HER2-positive metastatic breast cancer significantly improved survival from the time central nervous system metastases were diagnosed. (medicalxpress.com)
  • It is surprising that chemotherapy/trastuzumab adds to these women's survival," Brufsky said. (medicalxpress.com)
  • Median progression-free survival (PFS) improved from 4.9 months with investigator's choice of chemotherapy to 7.0 months with trastuzumab duocarmazine (SYD985). (medpagetoday.com)
  • A new clinical trial has shown that reducing the interval between successive doses of a commonly used chemotherapy regimen improves survival in women whose breast cancer has spread to the lymph nodes. (scienceblog.com)
  • While previous research has evaluated the use of various forms of "dose dense" chemotherapy, this is the first major controlled study to show a clear survival benefit for women with node-positive breast cancer. (scienceblog.com)
  • With the availability of new drugs to control one of the most serious side effects of chemotherapy administration, we can further increase the chances of survival for women with breast cancer. (scienceblog.com)
  • In addition to improved disease-free survival, the study indicated that dose dense chemotherapy may also lead to higher overall survival rates. (scienceblog.com)
  • A team of medical researchers in Italy have achieved what they are calling "excellent" tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. (survivingmesothelioma.com)
  • Post-operative chemotherapy improves disease-free survival. (uroweb.org)
  • For patients with advanced non-small cell lung cancer (NSCLC) harboring the ALK gene rearrangement, ceritinib (Zykadia) provided longer progression-free survival than chemotherapy in patients previously treated with chemotherapy and crizotinib (Xalkori), but gastrointestinal toxicity was. (ascopost.com)
  • Newer studies with intensive multiagent chemotherapy (eg, the CALGB [Cancer and Leukemia Group B]- 8811 and hyper-CVAD [hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone] regimens and the ALL-2 regimen) plus the addition of TKIs for Ph+ ALL and rituximab for CD20-positive ALL have resulted in 3-y survivals of 50% or more in adults. (medscape.com)
  • In these patients who are poor candidates for resection, a combination of chemotherapy, locoregional therapies like ablation, transarterial chemo and radioembolization, and in very advanced and metastatic disease, external radiation are the available options. (mdpi.com)
  • As reported in The New England Journal of Medicine by Yuichiro Doki, MD, of Osaka University Graduate School of Medicine, Japan, and colleagues, the phase III CheckMate 648 trial has shown improved overall survival with nivolumab combined with chemotherapy or ipilimumab vs chemotherapy alone in. (ascopost.com)
  • In the phase III RATIONALE-302 trial reported in the Journal of Clinical Oncology, Shen et al found that the anti-PD-1 antibody tislelizumab significantly improved overall survival vs chemotherapy in the second-line treatment of patients with advanced or metastatic esophageal squamous cell. (ascopost.com)
  • Docetaxel-based chemotherapy regimens have substantially improved survival and recurrence rates for cancer patients. (hindawi.com)
  • Furthermore, lenograstim may increase the patient's exposure to chemotherapy allowing patients to receive optimal dosing and duration of treatment, benefitting survival. (hindawi.com)
  • Systemic adjuvant chemotherapy with anthracycline- and taxane-containing regimens has become the standard first line treatment for early and metastatic breast cancer [ 5 ], with large phase III randomized trials showing extremely high long-term disease-free survival and overall survival rates (resp. (hindawi.com)
  • In fact, reducing the planned dose intensity of systemic adjuvant chemotherapy regimens by as little as 15% has been shown to significantly reduce time to progression and overall survival rates in women with metastatic breast cancer [ 5 ]. (hindawi.com)
  • G-CSFs have been shown to reduce overall mortality risk [ 8 , 11 ], reduce the incidence of other adverse events (grade 2 or greater anaemia, asthenia, anorexia, myalgia, nail disorders, and oral mucositis) associated with docetaxel-based chemotherapy regimens, and increase health related quality of life and consequently treatment compliance [ 8 , 12 ]. (hindawi.com)
  • From then on I decided not to operate on patients immediately if they were tumor-free after radiation and chemotherapy. (fapesp.br)
  • Treatment with ATRA and anthracycline-based chemotherapy (ATRA + chemotherapy) decreases relapses of the disease as well as early hemorrhagic deaths. (druglib.com)
  • Vectibix was approved in the U.S. in September 2006 as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin and irinotecan chemotherapy regimens. (fiercepharma.com)
  • Compared to placebo, niraparib significantly prolonged the second progression-free survival, time to first subsequent treatment, and chemotherapy-free interval in the mutation and mutation-free groups, and in the HRD subgroup. (esmo.org)
  • In breast cancer patients, we believe there is now sufficient evidence to suggest that the administration of LHRHa could be considered a potential standard strategy to preserve ovarian function and might also play a role in increasing the likelihood of pregnancy after chemotherapy," said Lambertini. (oncologynurseadvisor.com)
  • Imlygic) was associated with a significant improvement in 5-year survival outcomes, including overall survival, compared with surgery alone in patients with advanced resectable melanoma , new data suggest. (medscape.com)
  • These results demonstrate that neoadjuvant T-VEC plus surgery improves cancer-related outcomes vs surgery alone, with acceptable safety,' the authors concluded, adding that the improvement in survival outcomes 'is likely the result of an induced systemic immunologic antitumor effect, as shown by elevated CD8+ density after T-VEC treatment. (medscape.com)
  • The availability of regimens containing one or more immune-checkpoint inhibitors (ICIs) has improved the outcomes in patients with advanced-stage hepatocellular carcinoma. (nature.com)
  • Building on this past research, the team assessed whether the treatment combination could also improve outcomes in early breast cancer. (nepalnews.com)
  • Our academic teams are dedicated to finding new treatments with scientific merit and the promise to improve outcomes for patients with sarcomas. (prnewswire.com)
  • The study's primary end point was ORR, with key secondary outcomes including safety, investigator-assessed progression-free survival (PFS), and overall survival (OS). (cancernetwork.com)
  • Case series and cross-sectional studies of HTLV-I and -II disease outcomes are vulnerable to potential bias and confounding. (cdc.gov)
  • We report on the occurrence of various disease outcomes in this cohort after a median follow-up of 4.3 years. (cdc.gov)
  • Reproductive and obstetrical outcomes with the overall survival of fertile-age women treated with fertility-sparing surgery for borderline ovarian tumors in Sweden: a prospective nationwide population-based study. (cancercentrum.se)
  • While localized melanoma has an excellent prognosis, regional and distant disease is associated with much poorer outcomes. (medscape.com)
  • The trial met its primary endpoint, with niraparib considerably prolonging progression-free survival compared to placebo. (esmo.org)
  • Niraparib significantly improved the primary endpoint of progression-free survival compared to placebo in both cohorts, as well as in all subgroups. (esmo.org)
  • The rate (75 percent) and timing (median 7.0 weeks) of crossover from the BSC alone arm to receiving panitumumab, and the anti-tumor activity observed after crossover, likely confounded the ability to demonstrate a treatment effect on overall survival (Hazard ratio = 0.93). (amgen.com)
  • Over a median follow-up of 63.3 months, 5-year recurrence-free survival was 22.3% in group 1 and 15.2% in group 2 (hazard ratio [HR], 0.76). (medscape.com)
  • The study population had a median age of about 57, a median duration of metastatic disease of 3 to 3.5 years, and a median of four to five prior metastatic regimens. (medpagetoday.com)
  • The median five-year survival drops significantly from about 80% with the presence of regional or distant metastasis. (wikipedia.org)
  • 0001). Median progression-free survival was not reached in the obinutuzumab group, but was 13.8 months in the group receiving bendamustine alone. (medscape.com)
  • The median overall survival has not yet been reached in either study group. (medscape.com)
  • The log rank test on the Kaplan-Meier survival analysis revealed that there was no significant difference (p=0.591) in OS between TTE (median survival=52.6 months), MIE (median survival = 39.73 months) and THE (median survival=29.71 months). (sages.org)
  • other endpoints included overall survival, event-free survival, and distant metastasis-free survival. (medscape.com)
  • Immune response to the PR1 vaccine was associated with an 8.7 month event-free survival compared with 2.4 months for non-responders. (algodonwineestates.com)
  • We did not expect dramatic responses in this clinical trial, and were pleasantly surprised to see the clinical responses and improved event-free survival' says Muzaffar Qazilbash, M.D., associate professor in M. D. Anderson's Department of Stem Cell Transplantation and Cellular Therapy. (algodonwineestates.com)
  • In a planned interim analysis, 5-year event-free survival for patients who received the high-dose regimen was 82%, compared with 75% for those receiving the escalation protocol. (medscape.com)
  • Although event-free survival continues to improve for children and young adults with high-risk ALL, CNS disease has become an increasing site of treatment failure, the authors note. (medscape.com)
  • A landmark study showed that the investigational PARP (poly ADP-ribose polymerase) 1/2 inhibitor niraparib, when used as maintenance therapy, significantly improves the outcome of platinum-sensitive recurrent ovarian cancer. (ascopost.com)
  • The aim of this study was to analyse the long-term outcome of rectal cancer patients who submitted to preoperative chemoradiation with consecutive intensive follow-up and aggressive surgical treatment of recurrent disease. (researchgate.net)
  • Outcome of acute promyelocytic leukemia (APL) has greatly improved since the introduction of all-trans-retinoic acid (ATRA). (druglib.com)
  • Determine whether rapid reduction in tumor volume by chest radiography and CT scan is predictive of improved outcome in patients treated with these regimens. (knowcancer.com)
  • LUGANO-COPENHAGEN - The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine (NEJM). (esmo.org)
  • Invasive disease-free survival was the primary endpoint of the study. (nepalnews.com)
  • this is an important endpoint for these patients, in whom rapid worsening of the disease can lead to worse symptoms and life-threatening situations. (prnewswire.com)
  • Introduction: Radiographic progression-free survival (rPFS) by Prostate Cancer Working Group (PCWG) criteria is a radiographic endpoint. (lu.se)
  • Patients with central nervous system metastases were younger, and more likely to have hormone receptor negative disease and higher disease burden compared with those whose cancer did not spread to the brain. (medicalxpress.com)
  • Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a SweGCG study. (cancercentrum.se)
  • Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer - a Swedish Gynecologic Cancer Group (SweGCG) study. (cancercentrum.se)
  • Treatment with a new class of drugs, called senolytics, in donors improved the physical fitness of the recipients, a new study has shown. (medicaldaily.com)
  • A study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) - two immunotherapy agents - did not meet its main goal of disease-free survival (time a patient survives after treatment without signs or symptoms of their cancer) in certain patients with kidney cancer, according to Bristol Myers Squibb, the manufacturer of the drugs. (curetoday.com)
  • Even with notable progress in the treatment of metastatic (kidney cancer), there are still limited treatment options available for patients with localized disease," Dr. Dana Walker, vice president and development program lead of genitourinary cancers at Bristol Myers Squibb, said in a press release. (curetoday.com)
  • The main goal of the study was determining disease-free survival, with secondary goals of overall survival (time from treatment until death of any cause) and incidence of side effects. (curetoday.com)
  • Opdivo and Opdivo-based combinations have shown survival benefits in several earlier-stage and advanced cancers, including genitourinary tumors, and we are disappointed that the final analysis of CheckMate-914 Part A did not show this same benefit for the post-surgical treatment of patients with localized (kidney cancer)," Walker said. (curetoday.com)
  • Panitumumab treatment also showed a clinical benefit in the patients crossing over from the BSC arm, despite their disease progression. (amgen.com)
  • In these patients, panitumumab treatment resulted in a nine percent partial response and 32 percent stable disease, as well as one complete response. (amgen.com)
  • Treatment with SYD985 significantly improved progression-free survival in comparison with standard physician's choice treatment in patients with HER2-positive metastatic breast cancer with two prior regimens or T-DM1 (trastuzumab emtansine, Kadcyla) in the metastatic setting," she said in conclusion. (medpagetoday.com)
  • A study found that patients with early hormone-receptor (HR) positive/HER2 negative breast cancer had a significant advantage in invasive disease-free survival when ribociclib, a targeted therapy medicine, was added to hormone treatment. (nepalnews.com)
  • The TITAN final analysis further confirms that treatment with apalutamide can prolong overall survival and offer a clear long-term clinical benefit and established safety profile for patients with metastatic prostate cancer who are starting androgen deprivation therapy," said Dr. Kim Chi, Medical Oncologist at BC Cancer - Vancouver and principal investigator of the TITAN study. (jnj.com)
  • Educating children and adults in the disease process, treatment and prevention of head and neck cancer In addition to year-round events and awareness efforts such as benefit concerts and walkathons, the Alliance sponsors a week-long series of events to promote early detection and public awareness of this disease. (wikipedia.org)
  • People with follicular lymphoma whose disease returns or worsens despite treatment with a rituximab-containing regimen need more options because the disease becomes more difficult to treat each time it comes back," said Sandra Horning, MD, chief medical officer and head of global product development at Genentech. (medscape.com)
  • 20 - 25 ] A major pooled analysis evaluating the impact of T and N stage and treatment on survival and relapse in patients with rectal cancer who are treated with adjuvant therapy confirmed these findings. (cancer.gov)
  • Nevertheless, treatment options have substantially improved survival rates. (hindawi.com)
  • According to findings from the REMOVAL trial, metformin may be an effective long-term treatment to reduce the risk of heart disease among patients with type 1 diabetes. (pharmacytimes.com)
  • The investigators explored whether 3 years of treatment with metformin would reduce the risk of heart disease risk among 428 middle-aged patients with type 1 diabetes who are at risk of heart disease. (pharmacytimes.com)
  • A decrease in weight and insulin dose was more or less expected, however, we were surprised to discover a reduction in LDL-cholesterol and atherosclerosis progression with metformin treatment," said chief investigator John Petrie, MD, PhD. "The results of REMOVAL support wider prescribing of metformin to help reduce heart disease risk factors over a lifetime of type 1 diabetes, mirroring its current use in adults with type 2 diabetes. (pharmacytimes.com)
  • The rates of successful treatment and survival remain low and the 5-year survival rate is 21% ( 2 ), which may be attributed to the fact that NSCLC is usually diagnosed at an advanced stage, with no surgical options ( 6 , 7 ). (spandidos-publications.com)
  • Determine whether treatment with a regimen without methotrexate maintains the same disease-free survival as NHL/BFM 90 in these patients. (knowcancer.com)
  • Therefore, prediction of response to NACT is crucial to optimizing treatment plan and improving individual patient-tailored management. (springer.com)
  • The approach may increase the chances of pregnancy after breast cancer treatment by preventing premature ovarian failure (POF). (oncologynurseadvisor.com)
  • Both looked at the length of time women remained free of cancer after treatment (disease-free survival). (oncologynurseadvisor.com)
  • Fetal haemoglobin (HbF) induction is the primary treatment response, along with improved anaemia, reduced haemolysis, myelosuppression and decreased endothelial inflammation. (cdc.gov)
  • Hydroxyurea has proven clinical efficacy for SCA - treatment significantly reduces disease manifestations and prolongs survival. (cdc.gov)
  • We soon saw a dramatic increase in the number of Certified Tumor Registrars, hospital cancer programs, and treatment centers across the state. (cdc.gov)
  • Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment. (cancercentrum.se)
  • Primary treatment and relative survival by stage and age in vulvar squamous cell carcinoma: A population-based SweGCG study. (cancercentrum.se)
  • This treatment has greatly improved survival for people with both seminomas and nonseminomas. (medlineplus.gov)
  • The disease-free survival rate for Stage II and III cancers is slightly lower, depending on the size of the tumor and when treatment is begun. (medlineplus.gov)
  • An independent, central radiology review board assessed disease progression and tumor shrinkage. (amgen.com)
  • Improvements in progression-free survival and disease control also occurred regardless of age, sex, primary tumor location (colon versus rectum), or performance status. (amgen.com)
  • I think over the next 10 years we will be able to define the best combination strategies of the ADCs that can lead to improvement in the delivery to the tumor tissue and improve immune response to the ADC to improve target expression and internalization of the payload activity. (medpagetoday.com)
  • When she told her patient the news that she was cured, Habr-Gama was asked in reply: "If I was tumor-free, why did you operate on me in the first place? (fapesp.br)
  • The results suggest that those patients who were recurrence-free three years after diagnosis had less than a 5% risk of tumor regrowth and only a 2% risk of metastasis. (fapesp.br)
  • The most notable finding in the paper is in its analysis of conditional survival, or the chances of a patient remaining disease-free after each year without tumor regrowth. (fapesp.br)
  • However, our research found that after a person has been tumor-free for three years, the risk of relapse becomes negligible," says lead study author Rodrigo Oliva Perez, who also works at the Angelita and Joaquim Gama Institute. (fapesp.br)
  • However, in recent years, there has been increasing evidence that metformin exerts its anticancer effects through the inhibition of oxidative phosphorylation (OXPHOS) of tumor cell mitochondria, and metabolic pathways based on metformin targeting have only recently become the focus of intensive research. (spandidos-publications.com)
  • Using the aBSI, we sought to quantify increase in tumor burden represented by PCWG progression criteria, and to determine the interval increase that best associates with overall survival (OS). (lu.se)
  • Many other areas of active research on this topic are ongoing, including investigations into improved selection criteria for patients undergoing SLNB based on features of the primary tumor, refinements in histopathologic and molecular evaluation of the sentinel node (SN), the prognostic importance of positive non-SNs and quality of life following the procedure, to name a few. (medscape.com)
  • The drug has significantly improved the prognosis of ovarian cancer patients. (hus.fi)
  • The current options for maintenance therapy in the EU are bevacizumab, which can only be given once and improves progression-free survival by just a few months, and the PARP inhibitor olaparib, which is only approved in patients with a germline BRCA mutation (about 10-15% of ovarian cancer patients). (esmo.org)
  • Niraparib significantly improved all endpoints across a broad patient population representing 70% of all ovarian cancer patients. (esmo.org)
  • Despite improved effectiveness, most systemic cancer therapies are not curative and most patients will develop acquired resistance that often cannot be explained by the emergence of specific genomic alterations. (nature.com)
  • Section 7.2 - Metastatic disease, systemic treatments, considerable new data has been added in both the first-line and second-line setting, not resulting in a change to the recommendations. (uroweb.org)
  • We conducted a [randomized], phase 2 study testing the hypothesis that either repeated low-dose fractionated radiotherapy or hypofractionated radiation would increase the systemic overall response rate to durvalumab-tremelimumab in patients with NSCLC who had previously progressed on PD(L)-1-directed therapy. (cancernetwork.com)
  • To be eligible for the study, patients needed to be 18 years of age or older with an ECOG performance status of 0 or 1, a life expectancy of 6 months or more, and evidence of disease progression on systemic PD-1/PD-L1 therapy. (cancernetwork.com)
  • Previously, Slamon and researchers at the Jonsson Cancer Center demonstrated that adding ribociclib, a cyclin-dependent kinase inhibitor, to the standard hormone therapy improves overall survival in both premenopausal and postmenopausal women with metastatic HR positive/HER2 negative breast cancer. (nepalnews.com)
  • The approval for the new indication of follicular lymphoma is based on data from the phase 3 GADOLIN study , which showed that obinutuzumab plus bendamustine followed by obinutuzumab alone led to a 52% reduction in progression-free survival in patients with relapsed disease, compared with bendamustine alone. (medscape.com)
  • The cohort involved 413 patients with indolent NHL - 321 with follicular lymphoma - whose disease progressed during or within 6 months of previous rituximab-based therapy. (medscape.com)
  • RARITAN, N.J., February 8, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA ® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT. (jnj.com)
  • Initial results from the TITAN study presented at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) and simultaneously published in The New England Journal of Medicine showed the addition of ERLEADA ® (apalutamide) to ADT compared to placebo plus ADT significantly improved the dual primary endpoints of OS and radiographic progression-free survival (rPFS) in patients with mCSPC. (jnj.com)
  • The study is limited by the definition and assessment of recurrence-free survival in the trial design, which does not account for disease progression during the neoadjuvant period. (medscape.com)
  • A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology. (medicaldaily.com)
  • Findings from the CheckMate-914 trial showed that Opdivo plus Yervoy did not meet the study's main goal of disease-free survival for patients with localized renal cell carcinoma, a type of kidney cancer. (curetoday.com)
  • Currently, the average five-year survival rate for patients with metastatic or advanced kidney cancer is 14%, and just over half of patients with resectable, localized disease experience a five-year disease-free survival. (curetoday.com)
  • 2 Third Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria. (nih.gov)
  • Women with HER2-positive breast cancer have a reasonable chance of living a long time with their disease, and they should be given aggressive therapy where appropriate," added Brufsky, professor of medicine and associate director of clinical investigation at the University of Pittsburgh Cancer Institute. (medicalxpress.com)
  • The authors of this Review present various approaches for delivering mRNA-LNPs to tumours and discuss improvements that will improve the selective targeting of cancer cells with mRNA-LNPs. (nature.com)
  • Researchers from UCLA Jonsson Comprehensive Cancer Centre found that individuals who received the combination therapy had much longer invasive disease-free life than those who received hormone therapy alone, regardless of whether the cancer had progressed to the lymph nodes. (nepalnews.com)
  • HR-positive/HER2-negative breast cancer is the most common subtype of the disease and accounts for nearly 70% of breast cancer cases in the Unites States. (nepalnews.com)
  • If confirmed and extended by additional research, this finding could positively affect the care of thousands of patients throughout the world with breast cancer and perhaps, eventually, other diseases. (scienceblog.com)
  • For one week during April, chapters of The Head and Neck Cancer Alliance and affiliates conduct free screenings, educational school talks, walkathons, fundraisers and other events in an effort to save lives via early detection, awareness, support, and education. (wikipedia.org)
  • The stage of the disease is a determining factor in deciding the prognosis of head and neck cancer. (wikipedia.org)
  • Nearly 8000 people die every year due to head and neck cancer, which is attributed to advanced stage disease at the time of diagnosis. (wikipedia.org)
  • Free screening clinics for head and neck cancers during Oral, Head and Neck Cancer Awareness week, sponsored by the Head and Neck Cancer Alliance, provides opportunities for earlier diagnosis of malignant cancer. (wikipedia.org)
  • free screenings are offered predominantly during Oral, Head and Neck Cancer Awareness Week in April at healthcare events and other related functions. (wikipedia.org)
  • The Head and Neck Cancer Alliance has also developed Head and Neck Check, a free iPad app to assist people with screening themselves for head and neck cancer. (wikipedia.org)
  • The U.S. approval for YONDELIS exemplifies our commitment to improving the health of people living with cancer and addressing unmet needs," said Roland Knoblauch , M.D., Ph.D., Clinical Leader, YONDELIS, Janssen Research & Development, LLC. (prnewswire.com)
  • Lynparza® (olaparib) is the first PARP inhibitor to demonstrate overall survival benefit in early breast cancer, according to new data. (europeanpharmaceuticalreview.com)
  • Delays in surgery for esophageal cancer did not appear to have much impact on patients' relative survival for early-stage cancer compared with patients who had surgery early, but they did reduce the relative survival rate by almost half for patients with more advanced disease, according to an. (ascopost.com)
  • South Africa is ranked 50th on the World Cancer Research Fund's list of countries with the highest cancer prevalence [ 1 ] and has recently been predicted to have a 78% increase in cancer cases by 2030 [ 2 ]. (hindawi.com)
  • Although the addition of radiotherapy did not increase responses vs durvalumab (Imfinzi) and tremelimumab alone for patients with PD-1/PD-L1-refractory metastatic non-small cell lung cancer (NSCLC), select patients may benefit from the PD-L1/CTLA-4 combination, according to findings from a phase 2 study (NCT02888743). (cancernetwork.com)
  • The rectum remaining cancer-free is the best predictor of a reduced risk of recurrence. (fapesp.br)
  • Non-communicable diseases, including breast cancer (BC), in Africa have been gaining more attention recently since improvements are seen in the management against infectious diseases, poor maternal health, and malnutrition. (karger.com)
  • More than 20% of these deaths from non-communicable diseases are cancer-related deaths [ 1 ]. (karger.com)
  • Background: There are few population-based data on the disease burden of cervical cancer from developing countries, especially South Pacific islands. (researchgate.net)
  • Objective: The objective of this study was to compare overall survival (OS) and disease free survival (DFS) among patients who underwent minimally invasive esophagectomy (MIE), trans thoracic esophagectomy (TTE) or trans hiatal esophagectomy (THE) for esophageal cancer. (sages.org)
  • We have never seen such large benefits in progression-free survival in recurrent ovarian cancer. (esmo.org)
  • Furthermore, the PROMISE-GIM6 study found that adding LHRHa made no difference to disease-free survival, even within the subgroup of women with hormone-receptor-positive breast cancer, who accounted for the majority of the patients enrolled in the study. (oncologynurseadvisor.com)
  • Pregnancy after breast cancer is safe, even in patients with endocrine-sensitive disease. (oncologynurseadvisor.com)
  • Reda Wilson has worked in cancer prevention and control more than 30 years, including 18 years at the Centers for Disease Control and Prevention's (CDC) Division of Cancer Prevention and Control. (cdc.gov)
  • I hope that over the next 30 years, NPCR and CDC increase our cancer surveillance, expand prevention resources, and continue to push toward a future free of cancer. (cdc.gov)
  • I'm pleased when I see reports showing decreasing cancer rates and improved survival. (cdc.gov)
  • CONCLUSIONS: An Inter-specialty Cancer Training Programme Curriculum and a pilot programme with virtual and face-to-face components have been developed with the aim of improving the care of people affected by cancer. (bvsalud.org)
  • C Predicts Improved Disease-Free Survival in Colorectal Cancer. (cdc.gov)
  • A new prospective study of more than 500 adults who were current smokers when diagnosed with lung cancer, published today in the Annals of Internal Medicine , provides robust evidence indicating that quitting smoking after diagnosis of lung cancer is associated with significant improvement in overall survival and disease-free survival among these patients. (who.int)
  • This study recruited 517 patients with newly diagnosed non-small cell lung cancer who were current smokers, from the departments of thoracic surgery at two sites in Moscow, Russian Federation, and followed them up annually for an average of 7 years to record any changes in their smoking behaviour and disease status. (who.int)
  • 1. Dahm-Kähler P, Palmqvist C, Staf C, Holmberg E, Johannesson L. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study. (cancercentrum.se)
  • No survival difference between robotic and open radical hysterectomy for women with early-stage cervical cancer: results from a nationwide population-based cohort study. (cancercentrum.se)
  • Panitumumab reduced the rate of disease progression by approximately half compared to best supportive care alone in these heavily pre-treated patients," said Marc Peeters, M.D., Ph.D., coordinator of Digestive Oncology Unit, University Hospital Ghent, and one of the study's lead investigators. (amgen.com)
  • Study investigators also reported that panitumumab significantly improved disease control versus BSC alone (36 percent versus 10 percent, respectively), as measured by response rate and stable disease. (amgen.com)
  • Investigators recruited patients from outpatient oncology clinics who had histologically or cytologically confirmed disease for the open-label, multicenter, randomized study. (cancernetwork.com)
  • The estimated glomerular filtration rate by the Modification of Diet in Renal Disease equation was observed to increase for patients starting metformin, but the investigators believe this finding needs to be studied further to determine the significance, according to the session. (pharmacytimes.com)
  • Studies have demonstrated that MIE improves peri-operative morbidity, however data on long term OS and DFS are lacking. (sages.org)
  • With the exception of obstructive symptoms, these symptoms do not necessarily correlate with the stage of disease or signify a particular diagnosis. (cancer.gov)
  • However, there remains a subset of the patients in whom the disease relapses. (druglib.com)
  • Ocular toxicity is the most prevalent safety event, and ILD [interstitial lung disease]/pneumonitis was reported, including grade 3 or worse, in 2.4% of patients. (medpagetoday.com)
  • Purpose To determine the value of minimal residual disease (MRD) assessments, together with the evaluation of clinical response in chronic lymphocytic leukemia according to the 2008 International Workshop on Chronic Lymphocytic Leukemia criteria. (nih.gov)
  • Disease-specific Phase II clinical trials of the vaccine for chronic myelogenous leukemia and myelodysplastic syndrome are planned or under way at M. D. Anderson. (algodonwineestates.com)
  • This review describes current considerations in the use of hydroxyurea for the management of sickle cell disease in the context of clinical severity. (cdc.gov)
  • An interim analysis of overall survival between the two groups was similar. (amgen.com)
  • The successes are mainly attributed to efforts of Ministry of Health (MOH) and its partners in the areas of malaria control, control of vaccine preventable diseases and improvement in prevention and case management of the main childhood killer diseases. (who.int)
  • Enrollment was stopped early because the survival difference crossed a predefined boundary, explained Dr. Larsen, and patients receiving the escalating-dose regimen were permitted to cross over to the high-dose regimen when feasible. (medscape.com)
  • HTLV-II participants had significantly increased incidences of acute bronchitis (incidence ratio [IR] = 1.68), bladder or kidney infection (IR = 1.55), arthritis (IR = 2.66), and asthma (IR = 3.28), and a borderline increase in pneumonia (IR = 1.82, 95% confidence interval [CI] 0.98 to 3.38). (cdc.gov)
  • HTLV-I participants had significantly increased incidences of bladder or kidney infection (IR = 1.82), and arthritis (IR = 2.84). (cdc.gov)
  • Apoptosis was significantly increased in the cells exposed to 50 microM of As (2.2-fold), Cr (4.5-fold), and Cd (2.5-fold). (cdc.gov)
  • Adding CRP to the well-established prognostic models such as the R-IPI score might improve their predictive ability. (nih.gov)
  • New sections 6.2.2 - Perioperative predictive tools for high risk disease and 6.3 - Bladder recurrence were added. (uroweb.org)
  • However, overall survival is the same whether a woman takes an aromatase inhibitor for 5 years or 10 years [ 109,312 ]. (komen.org)
  • The researchers found that two dose dense regimens provided significantly higher disease-free survival rates than two regimens using conventional dosing, and that efficacy did not differ between the two dose dense regimens. (scienceblog.com)
  • Among patients on the dose dense regimens, disease-free survival was 82 percent after four years, compared to 75 percent for those who received conventional therapy. (scienceblog.com)
  • In a Japanese case-control study reported in JAMA Oncology, Momozawa et al found that germline BRCA1/2 pathogenic variants were associated with an increased risk of biliary tract, esophageal, and gastric cancers, in addition to an increased risk of cancers that have well-established associations. (ascopost.com)
  • Increasing age is the most important risk factor for most cancers. (cancer.gov)
  • Models are available to predict non-organ confined disease and altered prognosis after RNU. (uroweb.org)
  • Among patients with measurable disease at baseline (about 85% of the population), the overall response rate was 28-29% in each group, but the average reduction in the target lesion was 70.2% with SYD985 versus 58.2% with standard therapy. (medpagetoday.com)
  • Since there was only a short-term reduction in A1C, improved glucose control was not able to elicit this effect, according to the session. (pharmacytimes.com)
  • Centers for Disease Control and Prevention. (cdc.gov)
  • In the area of non-communicable diseases, although lots remain to be done, the Ministry of Health is exerting its efforts in the provision of care to patients, with the establishment of dedicated NCD services including NCD corners in all health facilities & NCD clinics in health centers and above levels in all Zones. (who.int)
  • The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. (cdc.gov)
  • aBSI increase in bone disease was assessed from baseline scan to time-to-progression (per PCWG criteria). (lu.se)
  • The best association between OS and time-to-progression occurred with an absolute increase in aBSI equal to 0.6 (Kendall's tau 0.52). (lu.se)
  • The study indicates that training the brain to block out negative thoughts could improve symptoms of anxiety, depression, and PTSD. (medicaldaily.com)
  • The aim of this study was to evaluate the prognostic impact of pretreatment CRP levels on overall survival (OS) and disease-free survival (DFS) in a large bicentre study of DLBCL patients. (nih.gov)
  • The findings confirm the predictions of a mathematical model developed in the 1980s that suggested the value of increased dose density, which was the impetus for the study. (scienceblog.com)
  • The pivotal Phase 3 study enrolled over 500 patients and demonstrated an improvement in progression free survival (PFS) for patients treated with YONDELIS. (prnewswire.com)
  • The GADOLIN study evaluated the use of obinutuzumab plus bendamustine followed by obinutuzumab alone until disease progression or for up to 2 years, and compared it with bendamustine used alone. (medscape.com)
  • Since our study confirmed that metformin only improved blood sugar control in the very short term, guidelines in the US and United Kingdom should be updated to reflect the lack of a sustained effect of metformin on blood glucose levels in adults with type 1 diabetes," Dr Petrie said. (pharmacytimes.com)
  • It has been said that African patients present late with aggressive tumors and face a lack of therapeutic options, resulting in short survival duration. (karger.com)
  • All patients included had long-term diabetes and 3 or more cardiovascular disease risk factors, such as body mass index over 27, A1C greater than 8, known heart disease, smoking, high blood pressure, high cholesterol/triglycerides, family history of cardiovascular disease, or diabetes duration longer than 20 years, according to the session. (pharmacytimes.com)
  • Participants who consumed nine or more portions of ultra-processed foods daily had a 49% increased risk of depression compared to those who consumed less than four portions a day. (medicaldaily.com)
  • The data showed a statistically significant improvement in the risk of invasive disease in favour of the combination arm. (nepalnews.com)
  • Transcranial doppler (TCD) ultrasound screening, which identifies children with increased risk for stroke. (cdc.gov)
  • Information is lacking about the benefits and risks of genetic testing, the efficacy of early interventions, and the population distribution of genotypes and other risk factors associated with disease conditions. (cdc.gov)
  • Incidence of the disease in adults 50 years and older. (cancer.gov)